We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
GMTN | Gold Mountain Mining Corp | 0.035 | 0.005 | 16.67% | 40,635 |
APLI | Appili Therapeutics Inc | 0.04 | 0.005 | 14.29% | 21,001 |
GVC | Glacier Media Inc | 0.10 | 0.01 | 11.11% | 4,000 |
BKI | Black Iron Inc | 0.05 | 0.005 | 11.11% | 45,000 |
ASND | Ascendant Resources Inc | 0.065 | 0.005 | 8.33% | 20,000 |
NGD | New Gold Inc | 2.57 | 0.19 | 7.98% | 2,292,535 |
AEZS | Aeterna Zentaris Inc | 2.80 | 0.20 | 7.69% | 4,400 |
DYA | DynaCERT Inc | 0.15 | 0.01 | 7.14% | 79,074 |
EFR | Energy Fuels Inc | 7.61 | 0.48 | 6.73% | 329,914 |
WFC | Wall Financial Corp | 21.27 | 1.26 | 6.30% | 1,000 |
GLO | Global Atomic Corporation | 2.22 | 0.13 | 6.22% | 203,715 |
Canada's Leading Medical Cannabis Company and MedReleaf Australia Launch Innovative Product to Offer Greater Choice for Patients EDMONTON, AB, April 30, 2024 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – the Canadian based leading global medical cannabis company, in conjunction with MedReleaf Australia, is pleased to announce the expansion of its portfolio with the introduction of a new range of premium dried cannabis flower products. Now available for doctors to prescribe to patients in Australia, the new products developed by Aurora and manufactured at its EU-GMP and TGA-GMP certified facility, will be distributed by MedReleaf Australia, a premier distributor of medical ...
Annual Guidance Tracking to Plan, Growth Projects Make Meaningful Strides Towards Completion (All amounts are in U.S. dollars unless otherwise indicated) TORONTO, April 30, 2024 /CNW/ - New Gold Inc. ("New Gold" or the "Company") (TSX: NGD) (NYSE American: NGD) reports first quarter 2024 results. First quarter 2024 production totaled 70,898 gold ounces and 13.3 million pounds of copper as planned at an operating expense of $1,106 per gold ounce sold (co-product basis)3 and all-in sustaining costs1 of $1,396 per gold ounce sold (by-product basis). Another solid quarterly performance that delivered on plan, as the Company approaches a sustained free cash ...
EDMONTON, Alberta, May 01, 2024 (GLOBE NEWSWIRE) -- Capital Power Corporation (TSX: CPX) today released financial results for the quarter ended March 31, 2024. Financial highlights Generated adjusted funds from operations (AFFO) of $142 million and net cash flows used in operating activities of $334 millionGenerated adjusted EBITDA of $279 million and a net income of $205 million Strategic highlights Successful commissioning began on Genesee repower unit 1 simple cycle and retired Genesee 1, a significant milestone towards ...
The September 2022 Reclaim the Flame plan also included $150M in incremental digital and media investments through 2024 ("Fuel the Flame") followed by an agreement with franchisees to increase their investments in advertising from 2025-2028 should certain franchisee profitability metrics be achieved.
Rank | Ticker | Board Name | Posts (24h) |
---|---|---|---|
NWBO | NorthWest Biotherapeutics Inc | 282 | |
FNMA | Fannie Mae | 87 | |
COOP | Mr Cooper Group Inc | 57 | |
4 | RDGL | Vivos Inc | 48 |
5 | ELTP | Elite Pharmaceuticals Inc | 62 |
6 | CBDD | CBD Denver Inc | 28 |
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 56,889.38 | -3,710.90 | -6.12% | 1.12T | 7,878,391,028 |
ETH | Ethereum | 2,878.90 | -131.47 | -4.37% | 346.69B | 3,366,849,355 |
USDT | Tether USD | 0.99873 | -0.00042 | -0.04% | 97.72B | 460,599,273 |
BNB | Binance Coin | 545.51 | -32.07 | -5.55% | 86.28B | 526,711,944 |
SOL | Solana | 122.52 | -4.17 | -3.29% | 53.85B | 1,440,153,391 |
STETH | stETH | 2,882.13 | -126.57 | -4.21% | 28.29B | 14,346,542 |
USDC | USD Coin | 0.9999 | 0.00 | 0.00% | 28.07B | 1,177,859,036 |
XRP | Ripple | 0.4956 | -0.0044 | -0.88% | 27.07B | 372,326,841 |
DOGE | Dogecoin | 0.12068 | -0.01245 | -9.35% | 17.29B | 531,957,147 |
TONCOIN | Wrapped TON Coin | 4.63 | -0.533315 | -10.32% | 16.08B | 128,935,815 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions